Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer - Identification, prevention, and management

Journal of Supportive Oncology

Volumn 5, Issue 9, 2007, Pages 451-457

  Kang, Soonmo Peter ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BEVACIZUMAB; BRONCHODILATING AGENT; CETUXIMAB; CYTOTOXIC AGENT; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GLUCAGON; HYDROCORTISONE; HYPERTENSIVE AGENT; INFUSION FLUID; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PARACETAMOL; PLATINUM COMPLEX; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SALBUTAMOL; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VECTIBIX;

ABDOMINAL PAIN; ACNE; ACUTE LUNG INJURY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CANCER; DESENSITIZATION; DIAPHORESIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FLUID RESUSCITATION; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HOARSENESS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOPATHOGENESIS; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; PATIENT MONITORING; PREMEDICATION; PROTEINURIA; PRURITUS; RASH; RIGOR; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; STRIDOR; SYMPTOMATOLOGY; THORAX PAIN; THROMBOEMBOLISM; URTICARIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG HYPERSENSITIVITY; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 35648954031     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-397. [16461139]
2. Scarlet C. Ana phylaxis. J Infus Nurs 2006;29:39-44. [16429000]
3. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). August 9, 2006. National Cancer Institute's Cancer therapy Evaluation Program Website. Available at: http://ctep.cancer.gov/ forms/CTCAEv3.pdf. Accessed September 9, 2007.
4. Lieberman P. Anaphylaxis. Med Clin North Am 2006;90:77-95. [16310525]
5. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18:465-471. [10855789]
6. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006;20(5 suppl 2):5-13. [16736978]
7. Taxol (paclitaxel) [package insert]. Princeton, NJ; Bristol-Myers Squibb Co; 2003.
8. Eloxatin (oxaliplatin for injection) [package insert]. New York, Sanofi-Synthelabo Inc; 2004.
9. Paraplatin (carboplatin aqueous solution) (package insert]. Princeton, NJ; Bristol-Myers Squibb Co; 2004.
10. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004;9:546-549. [15477639]
11. Castells M. Rapid desensitization for hypersensitivity reactions to chemotherapy agents. Curr Opin Allergy Clin Immunol 2006;6:271-277. [16825867]
12. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89;477-481. [12888815]
13. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58:640-656. [16904789]
14. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005;36:3-10. [15848070]
15. Van Laan S: Monoclonal antibodies. American Medical Association Web site. April 11, 2005.Available at: http://www.ama-assn.org/ama/pub/ category/13280.html. Accessed November 29, 2005.
16. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-473. [16054760]
17. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003;17:143-152. [12818224]
18. Rituxan (rituximab) [package insert]. South San Francisco; Genentech, Inc; 2005.
19. Chu E, Devita VT. Physician's Chemotherapy Drug Manual 2006. Sudbury, Mass: Jones and Bartlett Publishers; 2006.
20. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61 (suppl 2):58-66. [11694789]
21. Avastin (bevacizumab) [package insert]. South San Francisco; Genentech, Inc; 2006.
22. Hart JW, Murillo JR, Oholendt MS, Preti HA. Assessment of safety with abbreviated, weight-based bevacizumab infusions in a variety of solid tumors. J Clin Oncol 2007;25(20S):19674.
23. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354.[15864276]
24. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Maher RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208. [14993230]
25. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. [15269313]
26. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:29-31. [16796788]
27. Erbitux (cetuximab) [package insert]. New York, NY/Princeton, NJ; ImClone Systems Inc/Bristol-Myers Squibb Co; 2005.
28. Bonner JA, Harari PM, GiraltJ, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. [16467544]
29. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002;29:55-60. [12422314]
30. TimoneyJ, Chung KY, Park V, Trocola R, Peake C, Saltz LB. Cetuximab use without chronic antihistamine premedication. J Clin Oncol 2006,24(18S):13521.
31. Thomas M. Current topics in colorectal cancer: targeting EGFR. Oncology Nursing Society Web site. Available at: http://www.ons.org/publications/ journals/pdfs/300519.pdf. Accessed September 1, 2007.
32. Vectibix (panitumumab) [package insert]. Thousand Oaks, Calif; Amgen; 2006.
33. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609. [17522249]
34. Tole JW, Lieberman P. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am 2007;27:309-326. [17493505]
35. Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:118-124. [16945167]
36. Peeters M, Cutsem V, Berlin J, et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor, in patients with metastatic colorectal cancer across clinical trials. J Clin Oncol 2007;25(20S):4138.
37. Ream MA, Tunison D. Hypersensitivity reactions. In: Yasko JM, ed. Nursing Management of Symptoms Associated with Chemotherapy. Bala Cynwyd, PA: Meniscus Health Care; 2001:213-224.
38. Chung CH, Chan E, Berlin J, et al. Cetuximab-related hypersensitivity reactions associated with pre-existing cetuximab-specific IgE antibody. J Clin Oncol 2007;25(20S):9097.
39. Allen RM, Goldberg RM, Berlin J, et al. Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: association with atopic phenotype. J Clin Oncol 2007;25(20S):9051.
40. Siena S, Glynne-Jones R, Thaler J, et al. Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer: findings from the MABEL study. J Clin Oncol 2007;25(205):4137.
41. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007;6:529-531. [17553202]
42. Langerak AD, Mitchell E, Cheema P, River GL, Shing M. Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer patients intolerant to cetuximab. J Clin Oncol 2007;25(20S):14579.